INTRODUCTION
The number of proteases known to contain a zinc atom in their catalytic sites has rapidly increased during the last few years and will doubtless continue to grow [1, 2] . Several of them have been identified as playing important physiological roles [3] [4] [5] , and therefore considerable efforts are currently being made to regulate their functions using new potent and highly selective synthetic inhibitors. Although potent and selective inhibitors of a few wellknown members of the zinc metalloprotease family (thermolysin, carboxypeptidase A, angiotensin-converting enzyme and neprilysin) are available [6] , for most of the other members such inhibitors remain to be developed.
For several years, our laboratory has been involved in the development of inhibitors of bacterial collagenases, enzymes that also belong to the zinc metalloprotease family [7] [8] [9] [10] . The most intensively studied collagenases have been those from Clostridium histolyticum which hydrolyse collagen, gelatin and peptides containing proline at the Xaa-Gly bond in Xaa-Gly-Pro-Yaa sequences [11, 12] . Other microbial collagenases, including those from Acromobacwer iophagus [13] , Bacillus cereus [14] , Treponema denticola [15] and Corynebacterium rathayii [16, 10] , have also been shown to degrade collagen, gelatin and the synthetic substrate furylacryloyl-Leu-Gly-Pro-Ala. Both The development of potent inhibitors of bacterial collagenases is an important goal as several studies have underlined their role in some human pathogenesis [14] . More specifically, collagenases produced by certain bacteria of the human flora are considered to be involved in the aetiology of periodontal disease [17] . More generally, the involvement of other bacterial zinc metalloproteases in human pathogenesis, such as those produced by Serratia marcescens and Pseudomonas aeruginosa (two microorganisms considered to be major causative agents of many opportunistic infections), should reinforce the current interest in developing potent inhibitors of these bacterial zinc proteases [18] [19] [20] .
One attractive approach to the development of potent inhibitors of zinc proteases involves synthesis ofpeptide substrate analogues in which the scissile peptide bond is replaced by the tetrahedral phosphonamide moiety (PO2NH) [21] [22] [23] . In fact, several studies of these phosphonamide inhibitors have demonstrated the usefulness of this strategy and have convincingly supported the view that these molecules act as transition-state analogues of the equivalent peptide substrates [24, 25] . In the case of bacterial collagenases, phosphonamide peptides with the general structure R-K(PO2NH)-Gly-Xaa-Yaa (R being an arylalkyl group and Xaa and Yaa being amino acids) also proved to be potent inhibitors of these collagenases [9] . However, it should be stressed that a major limitation to the use of phosphonamide derivatives is the chemical instability of the phosphonamide 
EXPERIMENTAL Materials
Collagenase from C. rathayii [16] was purified from a crude extract by a two-step procedure. This material (1 mg/ml) was loaded on to a gel-filtration column (TSK SW3000; Tosho) equilibrated with 50 mM Tricine/NaOH buffer, pH 7, containing 10 mM CaCl2 and 50 mM NaCl. Further purification was achieved by f.p.l.c. on an anion-exchange column (Mono Q; Pharmacia). The enzyme was eluted by applying an NaCl gradient (0.05-1 M). The major peak, containing activity against the furylacryloyl-Leu-Gly-Pro-Ala substrate, when analysed by SDS/PAGE, shows a single band in the 81 kDa molecular-mass range.
Assay of collagenase
Unless otherwise noted, all assays were performed under the following buffer conditions: 25 'C, pH 7.5, 50 mM Tricine/ NaOH, containing 10 mM CaCl2, 1 M NaCl and 1.25 mg/ml 1- O-octyl-/3-D-glucopyranoside. The presence of both 1 M NaCl and the l-O-octyl-,8-D-glucopyranoside in the buffer resulted in substantial stabilization of collagenase activity without affecting the kinetic properties of the enzyme. Under these conditions, 0.1-1 nM samples of collagenase retain the same activity for 4 days at 25 'C. Collagenase activity was assayed using the synthetic substrate furylacryloyl-Leu-Gly-Pro-Ala, as described by Van Wart and Steinbrink [28] . Enzyme concentration was determined spectrophotometrically using a molar absorption coefficient of 1.5 x I05 M-l cm-' at 280 nm.
Kinetic assays Reaction progress was measured spectrophotometrically by monitoring the release of furylacryloyl-Leu at 330 nm during hydrolysis of furylacryloyl-Leu-Gly-Pro-Ala. In a typical experiment, a cuvette containing 2 ml of buffer and 20 ,ul each of solutions of substrate and inhibitor was brought to thermal equilibrium (5-10 min) in a jacketed holder in the cell compartment of a Cary-219 spectrophotometer. The temperature was maintained by water circulating from a Haake P2 bath. Injection of [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] ,ul of enzyme initiated the reaction. Absorbance was continuously measured, digitized and stored in a Macintosh FX computer, equipped with a MacADIOS II Jr data-acquisition system (GW Instruments). As an interface between the acsoftware was used (Laboratory Technologies Corp.). Progress curves were composed of 500-1000 (absorbance, time) pairs.
Progress-curve analysis
Progress curves for the slow-binding inhibitors of collagenase were analysed using the integrated expression described by Morrison and Walsh [29] .
(1) where P is product concentration, v0 is the reaction velocity at t = 0, VS is the final steady-state velocity and kapp is the observed first-order rate constant for the approach to steady-state.
To investigate the kinetic mechanism of inhibition of collagenase by the present series of inhibitors, several progress curves at different inhibitor and substrate concentrations were recorded, and successfully fitted to eqn. (1) by non-linear leastsquares analysis. These procedures provide values for the three empirical parameters v0, VS and kapp
Determination of K, values
In some cases, slow-binding inhibitors impose long equilibrium times so that the equilibrium cannot be observed before complete depletion of the substrate. In these cases, measurements were made by equilibrating increasing concentrations of inhibitor in 2 ml of solution containing 0.1-1 nM enzyme overnight, and then initiating the reaction by adding 10 pl1 of substrate to determine the residual free enzyme concentration. Owing to the low dissociation rates for most of the inhibitors (see below), it was possible to neglect the effect of the addition of a competitive substrate on the equilibrium position. Determination of the equilibrium position makes it possible to calculate the K1 value using eqn. (2):
(2) which takes into account mutual depletion of enzyme (E) and inhibitor (I) [30, 31] .
Reversal of inhibition and determination of koff
The first-order rate constant for dissociation of the enzymeinhibitor complex was determined as follows: 0.5 ml of a solution of 1 ,tM collagenase and 10 ,uM inhibitor was incubated at room temperature for 20 min. This solution was then cooled to 4°C and loaded on a HR 10/10 fast desalting column (Pharmacia) that had been equilibrated at 4°C with 50 mM Tricine/NaOH buffer, pH 7.5, containing 10 mM CaCl2. The column was eluted at 4°C with this buffer, and the purified El complex fraction was pooled and then rapidly diluted with the pH 7.5 buffer composed of 50 mM Tricine/NaOH, 10 mM CaCl2, 1 M NaCl and 1.25 mg/ ml l-O-octyl-,/-D-glucopyranoside to produce a 1 nM stock solution of the El complex. This solution was kept at 25°C and 2 ml samples were assayed periodically for return of the enzyme activity by adding 5 ,ul of a 12 mM stock solution of the furylacryloyl-Leu-Gly-Pro-Ala substrate in dimethylformamide.
When the inhibitor levels required to produce complete progress curves that achieved steady-state velocities before appreci- 
Inhibition kinetics
In the absence of inhibitor, the steady-state rate of substrate hydrolysis by collagenase is reached instantaneously and remains nearly constant over the absorbance range monitored (Figure 1 ). In the presence of most phosphorus peptide inhibitors of the present series, there is a time-dependent decrease in the steadystate rate, which is a function of inhibitor concentration ( Figure  1 ). The reaction-progress curves, as shown in Figure 1 , were fitted to eqn. (1) by non-linear regression. The agreement between predicted and observed curves is satisfactory, indicating that this equation provides an adequate description of the inhibition.
From these fits, kapp.I the apparent first-order rate constant for the approach to steady-state, can be obtained for different inhibitor concentrations.
The slow-binding behaviour described by eqn. (1) is consistent with different mechanisms [32] . A single-step process is represented by mechanism A: 
The decrease in rate constant with inci centration indicates that compound 1 is a The solid lines in Figure 2 , predicte correspond to a second-order associatior 2.1 x I04 M-1 * s-' for compound 1. Similar slow-binding behaviour was ob 2 to 9 (results not shown). Second-order ass of compounds 2 and 4 with collagenase, procedure outlined for compound 1, are ( salient feature of these data is that the complex El is influenced by the stereocher of the residue in the P1 position of th4 inhibitors, the kon values for the D compc lower than that for the L compound.
The slow-or slow-tight-binding inhibi present inhibitors is not only due to ti formation, but results also from rate c( dissociation of the EI complex. Such rate to an average residence time in the enzym for compound 4, a very slow process compared with classic, even potent, inhibitors. From the data reported in Table 2 , it appears that the difference in activity observed between the L and D stereoisomers in mainly due to the lower association rate displayed by the D isomers, compared with the L isomers.
Values of Ki, as calculated from K, = k,,Jk0n, are in close agreement with those determined on the basis of percentage of activity observed at equilibrium.
DISCUSSION
Synthesis of phosphorus-containing analogues of peptide substrates appears to be a very attractive approach to the development of zinc metalloprotease inhibitors. In fact, this strategy makes possible the synthesis of inhibitors that could contain amino acid side chains in the Pn-Pn, positions capable of nding of Z-Phe-y,(PO2CH2)-interacting with the corresponding S.-Sn. subsites of the enzyme active cleft. Therefore it.should be suitable for developing specific inhibitors of zinc metalloproteases with a recognized extended itratTnsh60 pMot(2eKstabis)thadt active site, such as astacin [33, 34] , meprin A [35] , mammalian constant for association of Z-Phecollagenases [36] , gelatinases [37] and stromelysin [38] . Furthermore, as pointed out by Lolis and Petsko [39] 8 and 9) . These data underscore the critical role played by the C-terminal region of the inhibitor with respect to binding efficiency. Similar critical roles for the distal residues in either the C-or N-terminal portion of substrates and inhibitors on catalytic and binding efficiency have been reported for several proteases. Interestingly, Niedzwiecki et al. [38] reported that, for human stromelysin (a zinc protease), Nterminal truncation of the substrate results in a much greater reduction in catalytic efficiency than C-terminal truncation.
Under the experimental conditions used in this work, inhibition of bacterial collagenase by most of the inhibitors examined is consistent with a slow-binding mechanism as reviewed by Morrison and Walsh [29] . This inhibition behaviour is best described by mechanism A, a one-step process involving the slow binding of the inhibitor to the enzyme with no subsequent isomerization of the enzyme-inhibitor complex. However, it should be stressed that the two mechanisms are experimentally indistinguishable when the usable inhibitor concentration is one order of magnitude or more below the dissociation constant of the first enzyme-inhibitor complex in mechanism B [29] . The very low rates for both the association and dissociation steps of these inhibitors complicate the determination of both the K1 and k,ff values. In fact, experimental conditions under which enzyme activity is stable over a long period of time are required in order to determine these constants [44] . Several examples of such slow binding have been reported for enzyme inhibitors, some of which are transition-state analogues [29, 39] . Nevertheless, slow binding is by no means an absolute requirement for transition-state analogues. The exact origin of the slow-binding behaviourconformational changes, water displacement -is still very controversial, and cannot be addressed further at this stage of the study [45] . However, the influence of stereochemistry in the P1 position of the inhibitor on the ko. value is an interesting observation. In fact, as remarked by Kaplan et al. [44] , it would be fruitful to have a better understanding of the different factors that determine the kon value, in order to devise new inhibitors with faster association steps rather than very low off rates.
In conclusion, as compared with the series of arylalkylphosphonamide peptides previously reported [9] , this new series of compounds contains more potent inhibitors of bacterial collagenase. The greater potency of the phosphinic compounds results mainly from additional interactions provided by amino acid residues in the P4, P3 P2 and P1 positions of these new inhibitors. Another significant difference between these two series of inhibitors concerns their kinetic behaviour. Whereas the previously developed inhibitors exhibit classic kinetic properties, the present compounds are slow-tight-binding inhibitors, characterized by very slow on and off rates. Further studies are required to explain these differences.
